A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Recruiting

Phase 2

Zilovertamab VedotinA Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT05458297

Conditions

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Follicular Lymphoma

Richter Transformation Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Zilovertamab vedotin

Nemtabrutinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-07. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-10-30.